Market readiness, company capabilities and selecting a product with the right attributes are the three most important factors for securing a successful prescription-to-OTC switch, says Pfizer Inc.’s director of regulatory affairs for its Northern European cluster, Michelle Riddalls.
At the recent 13th Annual Ceuta International Alliance Conference in London, Riddalls told delegates that Pfizer had enjoyed “switch success” with the reclassification of Viagra Connect in the UK last...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?